{"id":"dm-choc-pen","_chembl":null,"modality":"Small molecule","_dailymed":null,"mechanism":{"explanation":"DM-CHOC-PEN is designed as a lipophilic alkylating-like agent that can penetrate the blood-brain barrier due to its cholesterol-based structure. Once inside tumor cells, it is believed to interfere with DNA synthesis and cell division, leading to cancer cell death.","oneSentence":"DM-CHOC-PEN is a polychlorinated pyridine cholesteryl carbonate designed to cross the blood-brain barrier and deliver anticancer activity to brain tumors."},"_scrapedAt":"2026-03-28T02:33:33.404Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123243,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"temozolomide","brand":"Temodar","company":"Merck","rationale":"Standard chemotherapy for glioblastoma and brain tumors"},{"name":"lomustine","brand":"Gleostine","company":"NextSource Biotechnology","rationale":"Alkylating agent used for brain tumors"},{"name":"carmustine","brand":"BiCNU","company":null,"rationale":"Nitrosourea alkylating agent for brain malignancies"}],"description":"DM-CHOC-PEN is an investigational small molecule anticancer agent developed by DEKK-TEC, Inc. currently in Phase 2 clinical trials. It is being studied for treatment of various cancers, particularly brain tumors and gliomas, where it may cross the blood-brain barrier.","indications":{"approved":[{"status":"investigational","condition":"Glioblastoma","patientPopulation":"Adult, recurrent disease"},{"status":"investigational","condition":"Brain metastases","patientPopulation":"Adult"},{"status":"investigational","condition":"Primary brain tumors","patientPopulation":"Adult"}]},"trialDetails":[{"nctId":"NCT03668847","phase":"PHASE2","title":"DM-CHOC-PEN for Brain Tumors in AYA Subjects","status":"COMPLETED","sponsor":"DEKK-TEC, Inc.","startDate":"2019-01-01","conditions":"Advanced Cancer, Brain Metastases","enrollment":20},{"nctId":"NCT03371004","phase":"PHASE1","title":"DM-CHOC-PEN Plus Radiation for Brain Tumors","status":"COMPLETED","sponsor":"DEKK-TEC, Inc.","startDate":"2016-02-05","conditions":"Advanced Cancer","enrollment":19},{"nctId":"NCT02038218","phase":"PHASE2","title":"Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome (DM-CHOC-PEN) in Patients With Brain Tumors","status":"COMPLETED","sponsor":"DEKK-TEC, Inc.","startDate":"2013-09","conditions":"Primary Brain Tumors, Metastatic Malignant Neoplasm to Brain","enrollment":29},{"nctId":"NCT02889445","phase":"","title":"A Phase I Trial of DM-CHOC-PEN in Adolescent and Young Adult (AYA) Subjects With Advanced Cancers","status":"NO_LONGER_AVAILABLE","sponsor":"DEKK-TEC, Inc.","startDate":"","conditions":"Advanced Cancer","enrollment":""},{"nctId":"NCT01048008","phase":"PHASE1","title":"Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer","status":"COMPLETED","sponsor":"DEKK-TEC, Inc.","startDate":"2010-09","conditions":"Advanced Cancer, Brain Involvement","enrollment":22},{"nctId":"NCT01976910","phase":"PHASE1","title":"Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer\"","status":"COMPLETED","sponsor":"DEKK-TEC, Inc.","startDate":"2010-09","conditions":"Advanced Cancer","enrollment":23}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["4-Demethylcholesteryloxycarbonylpenclomedine"],"phase":"phase_2","status":"active","brandName":"DM-CHOC-PEN","genericName":"DM-CHOC-PEN","companyName":"DEKK-TEC, Inc.","companyId":"dekk-tec-inc","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}